Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Ultragenyx Pharmaceutical (RARE) agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210M. The voucher was received after FDA approval of GENGLYCOS, a treatment for glycogen storage disease type Ia. The deal, subject to closing conditions, will provide non-dilutive capital to advance rare disease therapies and support profitability. Jefferies LLC and Gibson Dunn are advising Ultragenyx.
How this was made
The 30-second read
Why it matters
The $210 M transaction is a significant non‑dilutive financing event, likely to be viewed favorably by equity investors seeking cash‑rich biotech exposure.
Market read
First‑report of a $210 M voucher sale, a material capital‑raising event for a mid‑cap biotech, likely to move the stock.
What to watch
Potential tax implications of the voucher sale and the timing of the cash deployment into pipeline programs.
Background
Ultragenyx is a biopharma focused on rare and ultra‑rare genetic diseases. The company received the voucher after FDA approval of its GSDIa therapy, GENGLYCOS™.
Ticker impact
Ultragenyx announced a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $210 million, providing non‑dilutive cash to fund its pipeline.
upward pressure as the market prices in the $210 M non‑dilutive capital boost
Large, one‑time cash receipt from a regulatory voucher sale is material and uncommon, so investors typically react positively.
Market effects
May highlight the value of FDA priority review vouchers for other rare‑disease biotech firms.
Limited to US‑listed biotech sector; no broader regional effect.
Shows a monetization pathway for rare‑disease developers worldwide.
Counterpoint
Some investors may view the voucher sale as a sign that the company lacks sufficient internal cash flow, questioning long‑term sustainability.
Key entities
- companyUltragenyx Pharmaceutical Inc.
US‑listed biotech (NASDAQ: RARE) selling a priority review voucher.
- financial_advisorJefferies LLC
Exclusive financial advisor on the voucher transaction.
